文献速递皮肤肿瘤

MIA前哨淋巴结转移风险预测工具在美国国家癌症数据库中的外部验证

External validation of the Melanoma Institute Australia Sentinel Node Metastasis Risk Prediction Tool using the National Cancer Database.
PubMed 文献 · J Am Acad Dermatol · 2023-07-15

本研究利用美国国家癌症数据库(NCDB)对澳大利亚黑色素瘤研究所(MIA)的前哨淋巴结转移风险预测列线图进行外部验证,共纳入60,165例患者。结果显示该列线图在NCDB数据集中保持较高预测准确性(C统计量0.733,95%CI 0.726-0.739),但在最高风险十分位数校准减弱。

要点

  • MIA列线图在NCDB队列中C统计量为0.733(95%CI 0.726-0.739)。
  • 该列线图在最高风险十分位数校准减弱。
  • 验证结果提示该列线图有潜力预测前哨淋巴结阳性并减少阴性活检数。

核心结论

  • MIA列线图在美国国家癌症数据库中获得验证,显示出预测前哨淋巴结阳性的潜力,并可能减少阴性前哨淋巴结活检的数量。

研究设计与样本

  • 基于美国国家癌症数据库(NCDB)对MIA前哨淋巴结转移风险预测列线图进行外部验证,共纳入60,165例患者。

主要发现

  • NCDB队列的基线临床病理特征与原始MIA数据集不同。
  • MIA列线图在NCDB数据集中保持高预测准确性,C统计量为0.733(95%CI 0.726-0.739)。
  • 该列线图在最高风险十分位数校准减弱。

局限性

  • NCDB仅收集来自美国外科医师学会癌症委员会认证的医院登记处的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To improve patient selection for sentinel node (SN) biopsy, the Melanoma Institute of Australia (MIA) created a predictive model based on readily available clinicopathologic factors. OBJECTIVES: Validation of the MIA nomogram using the National Cancer Database (NCDB), a nationwide oncology outcomes database for >1500 Commission-accredited cancer programs in the United States. METHODS: A total of 60,165 patients were included in the validation. The probability of SN positivity was calculated for each patient. Using calculated probabilities, a receiver operating characteristic curve was generated to assess the model's discrimination ability. RESULTS: At baseline, the NCDB cohort had different clinicopathologic characteristics compared with the original MIA data set. Despite these differences, the MIA nomogram retained high-predictive accuracy within the NCDB dataset (C-statistic, 0.733 [95% CI, 0.726-0.739]), although calibration weakened for the highest risk decile. LIMITATIONS: The NCDB collects data from hospital registries accredited by the Commission on Cancer. CONCLUSIONS: In conclusion, this study validated the use of the MIA nomogram in a nationwide oncology outcomes database collected from >1500 Commission-accredited cancer programs in the United States, demonstrating the potential for this nomogram to predict SN positivity and reduce the number of negative SN biopsies.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Freeman SC, Paz Munoz E, Latour E, et al. External validation of the Melanoma Institute Australia Sentinel Node Metastasis Risk Prediction Tool using the National Cancer Database. J Am Acad Dermatol. 2023. PMID: 37454700. doi:10.1016/j.jaad.2023.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。